Skip to main content
. 2014 Jul 14;32(25):2718–2726. doi: 10.1200/JCO.2014.55.5094

Fig 1.

Fig 1.

Kaplan-Meier analyses of the impacts of BRAF V600E and TERT C228T mutations on disease-free survival of patients with papillary thyroid cancer (PTC). (A, B) Results of the analyses of patients with PTC of all types. (C, D) Results of the analyses of conventional variant PTC only. (A, C) Effects of the BRAF V600E mutation on tumor recurrence-free survival. (B, D) Effects of the TERT C228T mutation on tumor recurrence-free survival. Blue lines represent patients negative for the indicated mutation. Gold lines represent patients positive for the indicated mutation.